Who are Part B: Multiple-dose ATM-AVI, Cohorts 1-4's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Emtricitabine and Tenofovir, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Triple therapy with ritonavir, Emtricitabine/tenofovir disoproxil fumarate, Doravirine (DOR), Etravirine (ETR).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/part-b-multiple-dose-atm-avi-cohorts-1-4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 (part-b-multiple-dose-atm-avi-cohorts-1-4) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral. Area: Infectious Disease.

marketed Antiretroviral HIV-1 Infectious Disease Live · refreshed every 30 min

Target snapshot

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 (part-b-multiple-dose-atm-avi-cohorts-1-4) — Pfizer. The mechanism of part-b-multiple-dose-atm-avi-cohorts-1-4 is not specified.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Part B: Multiple-dose ATM-AVI, Cohorts 1-4 TARGET	part-b-multiple-dose-atm-avi-cohorts-1-4	Pfizer	marketed	Antiretroviral	HIV-1
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Oral Tablet	Emtricitabine / Tenofovir Disoproxil Oral Tablet	University of Chicago	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Triple therapy with ritonavir	Triple therapy with ritonavir	Sociedad Andaluza de Enfermedades Infecciosas	marketed	HIV protease inhibitor	HIV-1 protease
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Doravirine (DOR)	Doravirine (DOR)	Walter K. Kraft	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Etravirine (ETR)	Etravirine (ETR)	ViiV Healthcare	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral class)

A.O. Ospedale Papa Giovanni XXIII · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Pfizer · 1 drug in this class
University of Guadalajara · 1 drug in this class
ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Part B: Multiple-dose ATM-AVI, Cohorts 1-4 — Competitive Intelligence Brief. https://druglandscape.com/ci/part-b-multiple-dose-atm-avi-cohorts-1-4. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab